Bank Of America Corp Galectin Therapeutics Inc Transaction History

Bank Of America Corp

$1.19 Trillion
Q3 2024

A detailed history of Bank Of America Corp transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Bank Of America Corp holds 19,042 shares of GALT stock, worth $19,803. This represents 0.0% of its overall portfolio holdings.

Number of Shares

19,042

Previous 18,356 3.74%

Holding current value

$19,803

Previous $41,000 26.83%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.04 - $2.86 $1,399 - $1,961	686 Added 3.74%	19,042 $52,000
Q2 2024 Aug 14, 2024	BUY	$2.13 - $4.2 $7,716 - $15,216	3,623 Added 24.59%	18,356 $41,000
Q1 2024 May 15, 2024	BUY	$1.6 - $2.44 $14,561 - $22,206	9,101 Added 161.59%	14,733 $35,000
Q4 2023 Feb 14, 2024	BUY	$1.6 - $2.18 $43 - $58	27 Added 0.48%	5,632 $9,000
Q1 2023 May 12, 2023	SELL	$1.1 - $2.4 $374 - $816	-340 Reduced 5.72%	5,605 $11,000
Q4 2022 Feb 10, 2023	SELL	$1.03 - $1.66 $2 - $3	-2 Reduced 0.03%	5,945 $6,000
Q3 2022 Nov 14, 2022	SELL	$1.31 - $2.48 $2,423 - $4,588	-1,850 Reduced 23.73%	5,947 $10,000
Q2 2022 Aug 12, 2022	SELL	$1.19 - $1.74 $2,142 - $3,132	-1,800 Reduced 18.76%	7,797 $10,000
Q1 2022 May 16, 2022	BUY	$1.61 - $2.31 $4,900 - $7,031	3,044 Added 46.45%	9,597 $15,000
Q4 2021 Feb 08, 2022	BUY	$2.07 - $3.8 $2,144 - $3,936	1,036 Added 18.78%	6,553 $14,000
Q3 2021 Nov 15, 2021	SELL	$2.59 - $4.15 $17,353 - $27,805	-6,700 Reduced 54.84%	5,517 $21,000
Q2 2021 Sep 13, 2021	BUY	$2.07 - $5.1 $25,289 - $62,306	12,217 New	12,217 $40,000

Others Institutions Holding GALT

# of Institutions

Shares Held

9.65M

Call Options Held

1.16M

Put Options Held

1.98M

View Full List

About GALECTIN THERAPEUTICS INC

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $61.8M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

More about GALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Galectin Therapeutics Inc Transaction History